Drug intelligence / Profile preview

BSC-1401

Development stage: Discontinued
Lead developer: BiSiChem
Modality: Small Molecules

Overview

BSC-1401 is a small molecule drug initially developed by BiSiChem Co. Ltd. It was investigated primarily for the treatment of neoplasms (cancers). The drug's development status is discontinued, indicating that it is no longer actively pursued in clinical development. Specific details on its mechanism of action or molecular targets are not publicly available from the provided data. The compound was in preclinical stages before discontinuation.

Other names: BSC-1401BSC1401BSC 1401

Beyond the preview

Go deeper on BSC-1401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSC-1401.

Explore the full profile